Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.85 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.85 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.85 |
| ▸ | HRH2 | P25021 | 3/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.85 |
| ▸ | HRH1 | P35367 | 2/20 | 0.85 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.85 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.85 |
| ▸ | HTR1B | P28222 | 1/20 | 0.85 |
| ▸ | HTR2A | P28223 | 1/20 | 0.85 |
| ▸ | HTR7 | P34969 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.85 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.50 |
| ▸ | SCN4A | P35499 | 4/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramipexole SCHEMBL4802595 | 1.00 | DRD3 (0.85) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL4801696 | 0.98 | DRD3 (0.85) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL35376 | 0.92 | DRD3 (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Dexpramipexole SCHEMBL74780 | 0.92 | DRD3 (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL195775 | 0.92 | DRD3 (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL4801367 | 0.92 | DRD3 (0.76) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL3947668 | 0.91 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL42113 | 0.91 | ADRA2A (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL20524815 | 0.91 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL1193565 | 0.91 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318987-B1 | PROCESS FOR RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE AND COMPOUNDS THEREFOR | SYNTHON BV (NL) | 2005-08-10 | — | — | EP | claimed |
| US-6727367-B2 | QUATERNIZING PRAMIPEXOLE INTO OPTICAL ISOMERS VIA REACTING MONOBASIC ACID ADDITION SALT WITH OPTICALLY ACTIVE ACID FORMING DIASTEREOMERIC MIXED SALTS AND PRECIPITATING FROM SOLVENT TO FORM SEPARATED DIASTEREOMERS | SYNTHON BV (NL) | 2004-04-27 | — | — | US | claimed |
| US-20040068119-A1 | Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor | POSPISILIK KAREL (CZ) | 2004-04-08 | — | — | US | claimed |
| EP-1318987-A1 | PROCESS FOR RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE AND COMPOUNDS THEREFOR | Synthon B.V. (NL) | 2003-06-18 | — | — | EP | claimed |
| US-20020103240-A1 | Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor | SYNTHON IP INC. | 2002-08-01 | — | — | US | claimed |
| WO-2002022591-A1 | PROCESS FOR RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE AND COMPOUNDS THEREFOR | SYNTHON B.V. (NL) | 2002-03-21 | — | — | WO | claimed |
| EP-1318987-B1 | PROCESS FOR RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE AND COMPOUNDS THEREFOR | SYNTHON BV (NL) | 2005-08-10 | — | — | EP | disclosed |
| US-6727367-B2 | QUATERNIZING PRAMIPEXOLE INTO OPTICAL ISOMERS VIA REACTING MONOBASIC ACID ADDITION SALT WITH OPTICALLY ACTIVE ACID FORMING DIASTEREOMERIC MIXED SALTS AND PRECIPITATING FROM SOLVENT TO FORM SEPARATED DIASTEREOMERS | SYNTHON BV (NL) | 2004-04-27 | — | — | US | disclosed |
| US-20040068119-A1 | Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor | POSPISILIK KAREL (CZ) | 2004-04-08 | — | — | US | disclosed |
| EP-1318987-A1 | PROCESS FOR RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE AND COMPOUNDS THEREFOR | Synthon B.V. (NL) | 2003-06-18 | — | — | EP | disclosed |
| US-20020103240-A1 | Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor | SYNTHON IP INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002022591-A1 | PROCESS FOR RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE AND COMPOUNDS THEREFOR | SYNTHON B.V. (NL) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068119-A1 | Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor | NOTUM, SLC5A6, WEE2 | DRD3 3598/4885DRD2 2184/4885DRD4 1516/4885 |
| US-20020103240-A1 | Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor | NOTUM, SLC5A6, WEE2 | DRD3 3598/4885DRD2 2184/4885DRD4 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.